8月25日周一盘中，亚盛医药（AAPG）股价出现大幅下跌，跌幅达5.25%，引发市场关注。此次下跌主要受到生物医药板块整体走弱的影响。
据市场消息，港股生物医药股于周一普遍震荡回调。其中，欧康维视生物跌幅超过15%，百奥赛图和中国抗体跌幅均超过8.5%，亚盛医药跌幅超过6%。这一行业性下跌趋势可能是导致亚盛医药股价下跌的主要原因。
值得注意的是，尽管股价下跌，但亚盛医药近期获得了积极的分析师评价。中金公司维持亚盛医药"跑赢行业"评级，并将目标价上调19.3%至105港元。中金指出，考虑到公司GLORA-4研究进展及新适应症空间可见度提升，上调了目标价。这一目标价较当前股价仍有15.8%的上行空间。此外，中金还强调了亚盛医药上半年的业绩符合预期，以及其主要产品耐立克在新适应症获批后的高速增长。然而，这些积极因素似乎未能在当日抵消整体市场的下行压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.